University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:
Partnership Between ARUP and Medicover Expands Access to Companion Diagnostic in the European Union
A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union.
ARUP Laboratories, in close collaboration with BioMarin Pharmaceutical Inc., developed AAV5 DetectCDx™, a companion diagnostic that aids in the selection of adult patients with severe hemophilia A who are eligible for treatment with ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), a new gene therapy developed by BioMarin. To facilitate access to the test in Europe, BioMarin and ARUP have partnered with Medicover, which provides diagnostic and healthcare services in Europe, to perform the testing at one of their facilities located in Germany for all countries in Europe.
PlumCare and Fabric Genomics Announce a Strategic Partnership to Integrate the Fabric AI Platform with PlumCare’s FirstSteps™ Newborn Genome Screening Program in Greece
PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece. The goal of FirstSteps, a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years.
Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal PRIME Study Interim Look - Enrollment to Stop Due to Success
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis. The Company has adopted the DSMB's recommendation and will stop PRIME study enrollment to focus on analyzing and reporting the available data..